Breast Cancer Clinical Trials in Los Angeles

Showing 361-380 of 575 trials

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

NCT03652077

The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02390 in participants with select advanced malignancies.

Cervical CancerGastric CancerStomach Cancer+18 more

Incyte Corporation40 participantsStarted Sep 2018

Los Angeles, California, United States • Jackson, Mississippi, United States • Hackensack, New Jersey, United States +1 more locations

COMPLETEDPhase 2< 1 mile

Neoadjuvant GW572016 to Treat Breast Cancer

NCT00206427

We want to learn whether GW572016 is effective in breast cancers that have HER2.

Breast Cancer

Baylor Breast Care Center49 participantsStarted Aug 2004

Los Angeles, California, United States • Albuquerque, New Mexico, United States • Houston, Texas, United States

TERMINATEDPhase 3< 1 mile

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

NCT01077154

This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therapy for women with early-stage breast cancer, who are at high risk of disease recurrence.

Breast Cancer

Amgen4,509 participantsStarted Jun 2010

Birmingham, Alabama, United States • Tucson, Arizona, United States • Jonesboro, Arkansas, United States +456 more locations

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Neoadjuvant GW572016 to Treat Breast Cancer

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Breast Cancer Trials in Other Cities

NEOBREADS: Neoadjuvant Breast Diet Study

Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

The BEACON Study (Breast Cancer Outcomes With NKTR-102)

Study of ISB 1302 (CD3 Bispecific Ab) in HER2-positive Metastatic Breast Cancer

High-Intensity Interval Training for Stage I-III Breast Cancer Patients

Study Evaluating The Effects Of Neratinib After Adjuvant Trastuzumab In Women With Early Stage Breast Cancer

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2

Lisinopril or Coreg CR® in Reducing Side Effects in Women With Breast Cancer Receiving Trastuzumab

Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer

Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer

Other Conditions in Los Angeles